Heterogeneity of exhausted T cells in the tumor microenvironment is linked to patient survival following resection in hepatocellular carcinoma

References

• Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63(5):844–12. 10.1136/gutjnl-2013-306627.
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-2.
   PubMed Web of Science ®Google Scholar
• Hashimoto M, Kamphorst AO, Im SJ, Kissick HT, Pillai RN, Ramalingam SS, Araki K, Ahmed R. CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu Rev Med. 2018;69:301–318. doi:10.1146/annurev-med-012017-043208.
   PubMed Web of Science ®Google Scholar
• Budhu A, Forgues M, Ye Q-H, Jia H-L, He P, Zanetti KA, Kammula US, Chen Y, Qin L-X, Tang Z-Y, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006;10(2):99–111. doi:10.1016/j.ccr.2006.06.016.
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–499. doi:10.1038/nri3862.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Lu B, Kane LP. Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. J Immunol. 2014;193(4):1525–1530. doi:10.4049/jimmunol.1400557.
   PubMed Web of Science ®Google Scholar
• Bengsch B, Johnson AL, Kurachi M, Odorizzi PM, Pauken KE, Attanasio J, Stelekati E, McLane LM, Paley MA, Delgoffe GM, et al. Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion. Immunity. 2016;45(2):358–373. doi:10.1016/j.immuni.2016.07.008.
   PubMed Web of Science ®Google Scholar
• Pauken KE, Wherry EJ. SnapShot: T cell exhaustion. Cell. 2015;163(4):1038–1038. e1031. doi:10.1016/j.cell.2015.10.054.
   PubMed Web of Science ®Google Scholar
• Zhou G, Sprengers D, Boor PP, Doukas M, Schutz H, Mancham S, Pedroza-Gonzalez A, Polak WG, de Jonge J, Gaspersz M, et al. Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas. Gastroenterology. 2017;153(4):1107–1119. e1110. 10.1136/gutjnl-2013-306627.
   PubMed Web of Science ®Google Scholar
• Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545(7652):60. doi:10.1038/nature22079.
   PubMed Web of Science ®Google Scholar
• Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, McNamara KL, Granja JM, Sarin KY,Brown RA, et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med.2019;25(8):1251–1259.doi:10.1038/s41591-019-0522-3.
   Google Scholar
• Popovic A, Jaffee EM, Zaidi N. Emerging strategies for combination checkpoint modulators in cancer immunotherapy. J Clin Invest. 2018;128(8):3209–3218. doi:10.1172/JCI120775.
   PubMed Web of Science ®Google Scholar
• Gao Q, Qiu S-J, Fan J, Zhou J, Wang X-Y, Xiao Y-S, Xu Y, Li Y-W, Tang Z-Y. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25(18):2586–2593. doi:10.1200/JCO.2006.09.4565.
   PubMed Web of Science ®Google Scholar
• Wittekind C. Pitfalls in the classification of liver tumors. Pathologe. 2006;27(4):289–293. doi:10.1007/s00292-006-0834-1.
   PubMed Web of Science ®Google Scholar
• Sun H-C, Zhang W, Qin L-X, Zhang B-H, Ye Q-H, Wang L, Ren N, Zhuang P-Y, Zhu X-D, Fan J, et al. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol. 2007;47(5):684–690. doi:10.1016/j.jhep.2007.06.019.
   PubMed Web of Science ®Google Scholar
• Agarwal S, Gertler FB, Balsamo M, Condeelis JS, Camp RL, Xue X, Lin J, Rohan TE, Rimm DL. Quantitative assessment of invasive mena isoforms (Mena calc) as an independent prognostic marker in breast cancer. Breast Cancer Res. 2012;14(5):R124. doi:10.1186/bcr3318.
   PubMed Web of Science ®Google Scholar
• Feng Z, Jensen SM, Messenheimer DJ, Farhad M, Neuberger M, Bifulco CB, Fox BA. Multispectral imaging of T and B cells in murine spleen and tumor. J Immunol. 2016;196(9):3943–3950. doi:10.4049/jimmunol.1502635.
   PubMed Web of Science ®Google Scholar
• Bakdash G, Buschow SI, Gorris MA, Halilovic A, Hato SV, Sköld AE, Schreibelt G, Sittig SP, Torensma R, Duiveman-de Boer T, et al. Expansion of a BDCA1+CD14+ myeloid cell population in melanoma patients may attenuate the efficacy of dendritic cell vaccines. Cancer Res. 2016;76(15):4332–4346. doi:10.1158/0008-5472.CAN-15-1695.
   PubMed Web of Science ®Google Scholar
• Shipitsin M, Small C, Giladi E, Siddiqui S, Choudhury S, Hussain S, Huang YE, Chang H, Rimm DL, Berman DM, et al. Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality. Proteome Sci. 2014;12(1):40. doi:10.1186/1477-5956-12-40.
   PubMedGoogle Scholar
• Rodda LB, Lu E, Bennett ML, Sokol CL, Wang X, Luther SA, Barres BA, Luster AD, Ye CJ, Cyster JG, et al. Single-cell RNA sequencing of lymph node stromal cells reveals niche-associated heterogeneity. Immunity. 2018;48(5):1014–1028. e1016. doi:10.1016/j.immuni.2018.04.006.
   PubMed Web of Science ®Google Scholar
• Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda SM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. 2009;106(9):3360–3365. doi:10.1073/pnas.0813101106.
   PubMed Web of Science ®Google Scholar
• Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17(8):1453–1464. doi:10.1038/mt.2009.83.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 2010;70(22):9053–9061. doi:10.1158/0008-5472.CAN-10-2880.
   PubMed Web of Science ®Google Scholar
• Wu D, Sanin DE, Everts B, Chen Q, Qiu J, Buck MD, Patterson A, Smith A, Chang C-H, Liu Z, et al. Type 1 interferons induce changes in core metabolism that are critical for immune function. Immunity. 2016;44(6):1325–1336. doi:10.1016/j.immuni.2016.06.006.
   PubMed Web of Science ®Google Scholar
• Zheng C, Zheng L, Yoo J-K, Guo H, Zhang Y, Guo X, Kang B, Hu R, Huang JY, Zhang Q, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell. 2017;169(7):1342–1356. e1316. doi:10.1016/j.cell.2017.05.035.
   PubMed Web of Science ®Google Scholar
• Zhu J, Feng A, Sun J, Jiang Z, Zhang G, Wang K, Hu S, Qu X. Increased CD4+CD69+CD25- T cells in patients with hepatocellular carcinoma are associated with tumor progression. J Gastroenterol Hepatol. 2011;26(10):1519–1526. doi:10.1111/j.1440-1746.2011.06765.x.
   PubMed Web of Science ®Google Scholar
• Han Y, Guo Q, Zhang M, Chen Z, Cao X. CD69+CD4+CD25−T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-β1. J Immunol. 2009;182(1):111–120. doi:10.4049/jimmunol.182.1.111.
   PubMed Web of Science ®Google Scholar
• Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med. 2007;13(3):108–116. doi:10.1016/j.molmed.2007.01.003.
   PubMed Web of Science ®Google Scholar
• Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949–1955. doi:10.1200/JCO.2010.30.5037.
   PubMed Web of Science ®Google Scholar
• McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol. 2019;37:457–495. doi:10.1146/annurev-immunol-041015-055318.
   PubMed Web of Science ®Google Scholar
• Fahey LM, Wilson EB, Elsaesser H, Fistonich CD, McGavern DB, Brooks DG. Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells. J Exp Med. 2011;208(5):987–999. doi:10.1084/jem.20101773.
   PubMed Web of Science ®Google Scholar
• Jogdand GM, Mohanty S, Devadas S. Regulators of Tfh cell differentiation. Front Immunol. 2016;7:520. doi:10.3389/fimmu.82016.00520.
   PubMed Web of Science ®Google Scholar
• Zhou ZQ, Tong DN, Guan J, Tan HW, Zhao LD, Zhu Y, Yao J, Yang J, Zhang ZY. Follicular helper T cell exhaustion induced by PD-L1 expression in hepatocellular carcinoma results in impaired cytokine expression and B cell help, and is associated with advanced tumor stages. Am J Transl Res. 2016;8(7):2926–2936.
   PubMed Web of Science ®Google Scholar
• Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, Sato E, Fukuoka S, Tada Y, Tanaka A, et al. PD- regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci USA. 2019;116(20):9999–10008. doi:10.1073/pnas.1822001116.
   PubMed Web of Science ®Google Scholar